Page 1070 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 17

498. Georgilis K, Plomaritoglou A, Dafni U, Bassiakos Y, Vemmos neutropenic patients with cancer who are receiving antibacte-
K. Aetiology of fever in patients with acute stroke. J Intern Med. rial chemoprophylaxis with oral quinolones. Clin Infect Dis.
August 1999;246(2):203-209. 1995;20(4):907-912.
499. Benezra D, Kiehn TE, Gold JW, Brown AE, Turnbull AD, 515. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction
Armstrong D. Prospective study of infections in indwelling of outcome in cancer patients with febrile neutropenia: com-
central venous catheters using quantitative blood cultures. Am J parison of the Multinational Association of Supportive Care in
Med. 1988;85(4):495-498. Cancer risk-index score with procalcitonin, C-reactive protein,
500. Bow EJ. Point: fluoroquinolone-based antibacterial chemo- serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J
prophylaxis in neutropenic cancer patients works for defined Cancer Care (Engl). 2007;16(6):475-483.
populations, but must be used wisely. J Natl Compr Canc Netw. 516. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe
2004;2(5):433-444. sepsis not clinically apparent during the first twenty-four hours
501. Kleinberg M. Counterpoint: routine anti-bacterial prophylaxis of hospitalization in children with cancer, neutropenia, and
is not indicated in neutropenic patients with hematological fever: a prospective, multicenter trial. Pediatr Infect Dis J. June
maligancies. J Natl Compr Canc Netw. 2004;2(5):445-451. 2008;27(6):538-543.
517. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role
502. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in
neutropenic patients: new evidence, practical decisions. Cancer. of procalcitonin in febrile neutropenic patients: review of the
2006;107(8):1743-1751. literature. Infection. October 2008;36(5):396-407.
518. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect
503. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quino-
lone prophylaxis in afebrile neutropenic patients on microbial of IgM-enriched intravenous immunoglobulin (Pentaglobin)
resistance: systematic review and meta-analysis. J Antimicrob on endotoxaemia and anti-endotoxin antibodies in bone mar-
Chemother. 2007;59(1):5-22. row transplantation. Eur J Clin Invest. 1993;23(9):540-545.
519. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assess-
504. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis:
antibiotic prophylaxis reduces mortality in neutropenic patients. ment of primary antifungal prophylaxis in patients with hema-
Ann Intern Med. 2005;142(12, pt 1):979-995. tologic malignancies. Blood. 2003;101(9):3365-3372.
520. Meunier F. New methods for delivery of antifungal agents. Rev
505. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer Infect Dis. 1989;11(suppl 7):S1605-S1612.
BS, Johnson A. Oral antibiotic prophylaxis in patients with
cancer: a double-blind randomized placebo-controlled trial. 521. Schwartz S, Behre G, Heinemann V, et al. Aerosolized ampho-
J Pediatr. 1983;102(1):125-133. tericin B inhalations as prophylaxis of invasive aspergillus infec-
tions during prolonged neutropenia: results of a prospective
506. Wade JC, Schimpff SC, Newman KA, Wiernik PH. randomized multicenter trial. Blood. 1999;93(11):3654-3661.
Staphylococcus epidermidis: an increasing cause of infec-
tion in patients with granulocytopenia. Ann Intern Med. 522. Karp JE, Burch PA, Merz WG. An approach to intensive antileu-
1982;97(4):503-508. kemia therapy in patients with previous invasive aspergillosis.
Am J Med. 1988;85:203-206.
507. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome
due to viridans streptococci: a case-control study of predispos- 523. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole
ing factors. Clin Infect Dis. 1992;14(6):1201-1207. prevents invasive fungal infections in neutropenic patients
treated for hematologic malignancies: evidence from a
508. Weisman SJ, Scoopo FJ, Johnson GM, Altman AJ, Quinn JJ. meta-analysis of 3,597 patients. J Clin Oncol. 2003;21(24):
Septicemia in pediatric oncology patients: the significance of viri- 4615-4626.
dans streptococcal infections. J Clin Oncol. 1990;8(3):453-459.
524. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous
509. Marron A, Carratalà J, González-Barca E, Fernández-Sevilla A, and oral itraconazole versus intravenous and oral fluconazole
Alcaide F, Gudiol F. Serious complications of bacteremia caused for long-term antifungal prophylaxis in allogeneic hematopoi-
by Viridans streptococci in neutropenic patients with cancer. etic stem-cell transplant recipients: a multicenter, randomized
Clin Infect Dis. 2000;31(5):1126-1130. trial. Ann Intern Med. 2003;138(9):705-713.
510. Tunkel AR, Sepkowitz KA. Infections caused by viridans 525. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus
streptococci in patients with neutropenia. Clin Infect Dis. fluconazole for prevention of fungal infections in patients
2002;34(11):1524-1529. receiving allogeneic stem cell transplants. Blood. February 15,
511. Bow EJ, Louie TJ. Emerging role of quinolones in the prevention 2004;103(4):1527-1533.
of gram-negative bacteremia in neutropenic cancer patients 526. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin
and in the treatment of enteric infections. Clin Invest Med. versus fluconazole for prophylaxis against invasive fungal
1989;12(1):61-68. infections during neutropenia in patients undergoing hemato-
512. de Marie S, van den Broek PJ, Willemze R, van Furth R. Strategy poietic stem cell transplantation. Clin Infect Dis. 2004;39(10):
for antibiotic therapy in febrile neutropenic patients on selec- 1407-1416.
tive antibiotic decontamination. Eur J Clin Microbiol Infect Dis. 527. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or
1993;12(12):897-906. empirical antifungal treatment versus placebo or no treatment
513. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential pro- in patients with cancer complicated by neutropenia. BMJ.
phylactic oral and empiric once-daily parenteral antibiotics for 1997;314(7089):1238-1244.
neutropenia and fever after high-dose chemotherapy and autolo- 528. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal
gous bone marrow support. J Clin Oncol. 1994;12(5):1005-1011. prophylaxis in cancer patients after chemotherapy or hemato-
514. Bow EJ, Loewen R, Vaughan D. Reduced requirement for anti- poietic stem-cell transplantation: systematic review and meta-
biotic therapy targeting gram-negative organisms in febrile, analysis. J Clin Oncol. 2007;25(34):5471-5489.

Section05-O-ref.indd 17 1/20/2015 4:51:21 PM